Han merecido este reconocimiento: Alejandro Angulo, Jesús Arribas, Maite Ferrándiz, Jorge Grau, Javier Huarte y Sonia Santos.
Details
Nuestro socio Jesús Arribas participó, como ponente, en las XIII Jornadas del Tribunal de Marcas de la Unión Europea que se celebraron en Alicante el 15 y 16 de noviembre. Su intervención se centró en las medidas cautelares urgentes y escritos preventivos en ferias y eventos. http://www.icali.es/wp-content/uploads/2018/09/Jornadas-Marca-Tribunal-2018.pdf
Details
On 20 July 2018 the Council of Ministers approved a preliminary draft law which will partially amend the Trademark Act (17/2001) in order to incorporate the EU Trademark Directive (2015/2436/EC). Read More
Details
On 12 September 2018 Barcelona Commercial Court Number 5 dismissed a preliminary injunction request filed by Merck Sharp & Dohme (MSD) regarding the commercialisation of generic medicinal products comprising ezetimibe and simvastatin. Read more
Details
– Patent, Trademark, Copyright & Design litigation – Advice on licence agreements •Anti-counterfeiting actions – Domain name disputes – Unfair competition Authors Sonia Santos and Jesús Arribas Download This article first appeared in World Trademark Review Yearbook 2019/2020, a supplement to World Trademark Review, published by Globe Business Media Group – IP Division. To view the…
Details
General Court confirms likelihood of confusion between PRIMART and PRIMA European Union – Grau & Angulo EUIPO Board of Appeal found likelihood of confusion between PRIMART and PRIMA in Class 30 Court con rmed that signs were visually similar to an average degree, and phonetically similar to an higher-than-average degree Group of letters ‘prima’ contributed…
Details
On 6 April 2018 the Court of Appeal of Zaragoza confirmed the judgment issued by the Trial Court Number 1 of Zaragoza, which had sentenced the two defendants for importing thousands of counterfeit t-shirts from China.
Details
On 14 March 2018 the Barcelona Commercial Court Number 4 dismissed a patent infringement action brought by Novartis against the first generics in Spain of its valsartan and amlodipine medicinal product for the treatment of hypertension (Exforge). The court upheld the defendants’ counterclaim for invalidity of the asserted patent.
Details